Table 2.
Type of Infection and Antibiotic Therapy for Case and Control Patients With Active Infection in a Study of Daptomycin and Linezolid–Nonsusceptible Vancomycin-Resistant Enterococcus
| Case Patients | Control Patients | P Value | |||
|---|---|---|---|---|---|
| (n = 44) | (n = 35) | ||||
| Type of infection | |||||
| Bacteremia without focus | 11 | (25) | 0 | (0) | <.01 |
| Cystitis | 6 | (14) | 14 | (40) | .01 |
| Abscess (not skin) | 8 | (18) | 3 | (9) | .33 |
| Osteomyelitis | 3 | (7) | 5 | (14) | .46 |
| Pneumonia | 3 | (7) | 1 | (3) | .63 |
| CLABSI | 5 | (11) | 4 | (11) | .99 |
| CAUTI | 0 | (0) | 4 | (11) | .04 |
| Pyelonephritis | 2 | (5) | 0 | (0) | .50 |
| Empyema | 1 | (2) | 0 | (0) | .99 |
| Cellulitis | 1 | (2) | 2 | (6) | .19 |
| Peritonitis | 0 | (0) | 1 | (3) | .44 |
| Meningitis | 0 | (0) | 0 | (0) | |
| Septic arthritis | 0 | (0) | 0 | (0) | |
| Other | 4 | (9) | 1 | (3) | .28 |
| Antibiotic choice | |||||
| Linezolid | 19 | (43) | 17 | (49) | .63 |
| Daptomycin | 17 | (39) | 13 | (37) | .89 |
| Tigecycline | 7 | (16) | 1 | (3) | .07 |
| Quinupristin-dalfopristin | 4 | (9) | 0 | (0) | .12 |
| Vancomycin | 3 | (7) | 0 | (0) | .25 |
| Beta-lactam | 2 | (5) | 1 | (3) | .99 |
| Aminogylcoside | 1 | (2) | 1 | (3) | .99 |
| Fosfomycin | 0 | (0) | 2 | (6) | .19 |
| Nitrofurantoin | 0 | (0) | 0 | (0) | |
| Active therapy | 10 | (23) | 35 | (100) | <.001 |
| Time to active therapy, days | 3.10 | 3.33 | .35 | ||
Data are presented as No. (%) unless otherwise indicated. Fisher exact tests, as appropriate, were used to test significant differences. P value for time to active therapy was calculated using a signed-rank test.
Abbreviations: CLABSI, central line–associated bloodstream infection; CAUTI, catheter-associated urinary tract infection.